natgillin/translations-raw huggingface dataset:
LeukoScan is used in patients with suspected infection of the bone called osteomyelitis. 
Zdravilo LeukoScan se uporablja pri bolnikih s sumom na vnetje kosti, imenovano osteomielitis.
NAME OF MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION LeukoScan 0.31 mg, powder for solution for injection 0.31 mg lyophilised sulesomab, stannous chloride and stabilizers. 
IME ZDRAVILA IN POT(I) UPORABE ZDRAVILA LeukoScan 0,31 mg prašek za raztopino za injiciranje 0,31 mg liofiliziranega sulezomaba, kositrov klorid in stabilizatorji
Store in a refrigerator (2°C-8°C). 
Komplet - Shranjujte v hladilniku (2 °C - 8 °C).
In the unlikely event of a radiation overdose being administered with LeukoScan [99mTc], the absorbed dose to the patient may be reduced by increased oral or intravenous intake of fluids to promote excretion 
V primeru prevelike doze sevanja, prejete ob vnosu zdravila LeukoScan [99mTc], kar pa ni verjetno, se absorbirana doza lahko zmanjša s povečanim peroralnim ali intravenskim vnosom tekočin, kar pospeši
For diagnostic nuclear medicine investigations, the current evidence suggests that the adverse effects will occur with low frequency because of the low radiation doses incurred. 
Zaradi nizkih doz sevanja, ki so jim bolniki izpostavljeni, dosedanji dokazi nakazujejo, da se bodo pri diagnostičnih nuklearnih medicinskih preiskavah neželeni učinki redko pojavljali.
Summary of Normal Organ Dosimetry to an Average Adult Patient (70 kg) from an Intravenous Dose of LeukoScan Labelled with 750 MBq of Technetium-99m [Dose Estimate from 13 Subjects 26 Administrations] 
Povzetek doze, ki jo prejmejo normalni organi pri povprečnem odraslem bolniku (70 kg) po intravenskem vnosu zdravila LeukoScan, označenega s 750 MBq tehnecija-99m[ocenjena doza sevanja pridobljena na osnovi 13 oseb in 26 vnosov]
LeukoScan is reconstituted with 0.5 ml isotonic sodium chloride injection. 
LeukoScan rekonstituiramo z 0,5 ml izotonične raztopine natrijevega klorida za injiciranje.
In the unlikely event of the administration of a radiation overdose with LeukoScan, the absorbed dose to the patient may be reduced by increased oral or intravenous intake of fluids to promote excretion of the 
V primeru prevelike doze sevanja, prejete ob vnosu zdravila LeukoScan, kar pa ni verjetno, se absorbirana doza lahko zmanjša s povečanim peroralnim ali intravenskim vnosom tekočin, kar pospeši izločanje
After radiolabelling the antibody and diluting a 10 µl sample with 1.5 ml saline, immediately determine the radiochemical purity by Instant Thin Layer Chromatography on silica gel impregnated glass fiber strips, 1 × 9 cm using acetone as the solvent. 
Po radioaktivni označitvi protitelesa in spiranju 10µl vzorca z 1,5 ml 0,9% raztopine natriejvega klorida za injiciranje takoj določite radiokemijsko čistoto s tenkoplastno kromatografijo hitre izvedbe (ITLCInstant Thin Layer Chromatography) na s silikagelom impregniranih ploščicah iz steklenih vlaken, 1 x 9 cm, topilo je aceton.
4.7 Effects on ability to drive and use machines 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Študije o vplivu na sposobnost vožnje in upravljanja s stroji niso bile izvedene.
(77.5% vs. 75.8%, respectively). 
Diagostična natančnost pa je pri teh dveh pojavnih oblikah enaka (77,5% vs 75,8%).
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE AND 
A. IZDELOVALEC (IZDELOVALCI) BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK
Radionuclide procedures carried out on pregnant women also involve radiation doses to the foetus. 
Vsi postopki, ki vključujejo uporabo radionuklidov in so izvedeni na nosečih ženskah, hkrati pomenijo določeno obsevalno dozo za zarodek.
Image acquisition in analogue and/or digital word-mode and at least a 128 x 128 matrix is recommended. 
Priporočljivo je snemanje slike v analognem in/ali digitalnem modusu in z matriko
The recommended adult dose is 0.25 mg of Fab′ fragment labelled with 900 ± 200 MBq of technetium 99mTc pertechnetate (approximately 1.2 ml). 
Priporočeni odmerek za odrasle je 0,25 mg Fab' fragmenta, označenega z 900 ± 200 MBq tehnecijevega
6.6 Special precautions for disposal and other handling Read complete directions thoroughly before starting the preparation procedure. 
Preden pričnete s postopkom priprave natančno preberite celotno navodilo.
HAMA titers should be determined before repeated administration of LeukoScan. 
Pred ponovnim vnosom zdravila LeukoScan je potrebno določiti HAMA titre.
After use, the container should be disposed of as radioactive waste. 
Po uporabi je potrebno vsebnik zavreči kot radioaktivni odpadek.
Anaphylactic and other hypersensitivity reactions are possible whenever mouse protein materials are administered to patients. 
Kadar so bolnikom aplicirani mišji proteini, so anafilaktične in druge preobčutljivostne reakcije vedno možne.
These dose estimates assume a urinary bladder voiding interval of two hours. 
Te doze so ocenjene na osnovi predpostavke, da se mehur prazni vsaki dve uri.
Rehydrate with sterile, non-pyrogenic 99mTc Na pertechnetate. 
Rehidrirajte s sterilno, apirogeno raztopino natrijevega pertehnetata [99mTc].
BEFORE YOU USE LEUKOSCAN You should not use LeukoScan 0.31 mg, sulesomab,powder for solution for injection 
KAJ MORATE VEDETI, PREDEN BOSTE UPORABILI ZDRAVILO LEUKOSCAN Zdravila LeukoScan 0,31 mg, prašek za raztopino za injiciranje ne smete uporabiti
For reconstitution of lyophilised powder, with a sterile disposable syringe add 0.50 ml of saline injection into the shielded LeukoScan 3-ml vial. 
Za rekonstituiranje liofiliziranega praška s sterilno odstranljivo brizgo dodajte 0,5 ml 0,9% raztopine natrijevega klorida za injiciranje v 3ml vialo zdravila LeukoScan, nameščeno v zaščitnem vsebniku.
Using saline injection, bring the final volume of eluate solution to 1.0 ml. 
Dodajte toliko 0,9% raztopine natrijevega klorida za injiciranje, da bo končni volumen eluata znašal 1,0 ml.
NAME OF THE MEDICINAL PRODUCT LeukoScan 0.31 mg, powder for solution for injection 
IME ZDRAVILA LeukoScan 0,31 Prašek za raztopino za injiciranje
4.9 Overdose 
6.2 Inkompatibilnosti
If either are present, the 
Če je prisotno karkoli od naštetega, je potrebno zdravilo
ATC code: VO4D At the concentrations and activities used for diagnostic procedures, LeukoScan does not appear to exert 
V koncentracijah in ob aktivnostih, uporabljenih za diagnostične postopke, ni videti, da bi zdravilo LeukoScan izkazovalo kakršnekoli farmakodinamične učinke.
These values were calculated according to Medical Internal Radiation Dosimetry. 
Vrednosti so bile izračunane v skladu z MIRD
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH 
(IMETNIKI) DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA
RELEASE 
Izračunajte
• If you have ever received LeukoScan or another product made from a mouse antibody, your doctor should take a sample of blood for testing to be sure that you have not developed an allergy to it. 
• Če ste kadarkoli že prejeli zdravilo LeukoScan ali drugo zdravilo, pripravljeno iz mišjih protiteles,
Medicinal product subject to medical prescription 
Ponovni vnos (readministracija zdravila)
Your doctor will prepare the LeukoScan and the radioactive isotope technetium in a volume of 1.5 ml. 
Vaš zdravnik bo pripravil zdravilo LeukoScan in radioaktivni izotop tehnecija, pripravljeni volumen bo znašal 1,5 ml. 0,25 mg zdravila LeukoScan bo označenega s 740 - 1110 MBq tehnecija.
Each 3 ml vial contains 0.31 mg sulesomab (IMMU-MN3 murine Fab′-SH antigranulocyte monoclonal 
Komplet za pripravo 99mTc označenega zdravila LeukoScan Vsaka 3 ml viala vsebuje 0,31 mg sulezomaba (IMMU-MN3 fragmenti Fab'-SH antigranulocitnih natrijev klorid klorovodikova kislina (sledovi) natrijev acetat trihidrat
6.2 Incompatibilities This medicinal product must not be mixed with other medicinal products except those mentioned in 6.6 or 
To zdravilo se ne sme mešati z drugimi zdravili razen s tistimi, ki so navedena v poglavju 6.6 ali 12. 6.3 Rok uporabnosti: komplet - 48 mesecev rekonstituiran in radioaktivno označen material - 4 ure
Contains 0.31 mg lyophilised sulesomab, stannous chloride and stabilizers. 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT Vsebuje 0,31 mg liofiliziranega sulezomaba, kositrov klorid in stabilizatorje.
No induction of human anti-mouse antibody (HAMA) reactive with fragment was observed in any 
Pri nobenem od bolnikov, ki je prejel zdravilo LeukoScan, niso opazili indukcije človeških protiteles proti mišjim antigenom (HAMA), ki bi reagirali s fragmentom.
Immediately prior to use, contents of the vial are reconstituted in the unlabeled form to prepare LeukoScan [99mTc]. 
Za pripravo zdravila LeukoScan [99mTc] je potrebno z radioizotopom neoznačeno vsebino viale neposredno pred uporabo rekonstituirati.
The kit does not include the 
Ne shranjujte v
4.2 Posology and method of administration 
4.4 Posebna opozorila in previdnostni ukrepi
There was no doseresponse effect for imaging efficacy (sensitivity or specificity) over antibody doses ranging from 0.1 mg 
Pri odmerkih protiteles v razponu od 0,1 mg do 1,0 mg velikost odmerka ni vplivala na učinkovitost slikanja
It was intended for use only when other antibiotics were not suitable. 
Uporabljalo naj bi se le, kadar drugi antibiotiki ne bi bili primerni.
‘Complicated' means that the infection is difficult to treat. 
„Zapletena okužba“ pomeni, da jo je težko zdraviti.
If you are in a clinical trial and need more information about your treatment, contact the doctor who is giving it to you. 
Če ste vključeni v klinično preskušanje in potrebujete več informacij o zdravljenju, se obrnite na zdravnika, ki vam je zdravljenje predpisal.
Because the medicine blocks the production of new proteins, the bacteria cannot multiply and they eventually die. 
Ker zdravilo preprečuje tvorbo novih beljakovin, se bakterije ne morejo razmnoževati in končno odmrejo.
Tigecycline Accord was expected to be used to treat adults and children older than 8 years with complicated infections of the skin and soft tissue (the tissue below the skin), except foot infections in people with diabetes. 
Zdravilo Tigecycline Accord naj bi se uporabljalo za zdravljenje odraslih in otrok, starejših od 8 let, z zapletenimi okužbami kože in mehkih tkiv (tkiva pod kožo), razen okužb stopala pri osebah s sladkorno boleznijo.
As for every medicine, the company also provided studies on the quality of Tigecycline Accord. 
Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti zdravila Tigecycline Accord.
It works against the bacteria that cause infections by blocking the bacteria's ribosomes, the parts of the cell where new proteins are made. 
Deluje proti bakterijam, ki povzročajo okužbe, tako da preprečuje delovanje bakterijskih ribosomov, delov celice, kjer nastajajo nove beljakovine.
On 12 September 2017, Accord Healthcare Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Tigecycline Accord, for the treatment of certain complicated infections. 
Družba Accord Healthcare Limited je dne 12. septembra 2017 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP) , da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Tigecycline Accord, namenjenim zdravljenju nekaterih zapletenih okužb.
Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Tygacil, and did not need to be repeated for Tigecycline Accord. 
Študije o koristih in tveganjih zdravilne učinkovine pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Tygacil, zato jih ni treba ponoviti za zdravilo Tigecycline Accord.
Tigecycline Accord was developed as a ‘generic medicine'. 
Zdravilo Tigecycline Accord je bilo razvito kot „generično zdravilo“.
In its letter notifying the Agency of the withdrawal of the application, the company stated that it was withdrawing the medicine for marketing reasons because of the issues at the manufacturing site. 
Družba je v dopisu, s katerim agencijo obvešča o umiku vloge, navedla, da se je za umik vloge odločila zaradi razlogov v zvezi s trženjem zaradi težav na lokaciji proizvodnje.
The company informed the CHMP that there are no consequences for patients currently included in clinical trials using Tigecycline Accord. 
Družba je odbor CHMP obvestila, da umik nima nobenih posledic za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih zdravila Tigecycline Accord.
It was also intended to treat complicated infections in the abdomen (belly). 
Namenjeno naj bi bilo tudi zdravljenju zapletenih okužb v trebuhu.
This means that Tigecycline Accord contains the same active substance and was intended to work in the same way as a ‘reference medicine' already authorised in the European Union called Tygacil. 
To pomeni, da vsebuje enako zdravilno učinkovino in ima enak način delovanja kot „referenčno zdravilo“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilo Tygacil.
There was no need for ‘bioequivalence' studies to investigate whether Tigecycline Accord is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. 
Izvedba študij biološke enakovrednosti, s katerimi se proučuje, ali se zdravilo Tigecycline Accord absorbira podobno kot referenčno zdravilo in tako ustvari enake ravni zdravilne učinkovine v krvi, ni bila potrebna.
Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Tigecycline Accord could not have been approved to treat complicated infections. 
Odbor CHMP je na podlagi pregleda podatkov ob umiku vloge izrazil določene zadržke in je začasno menil, da zdravila Tigecycline Accord ni mogoče odobriti za zdravljenje zapletenih okužb.
Tigecycline Accord is an antibiotic medicine that contains the active substance tigecycline. 
Tigecycline Accord je antibiotično zdravilo, ki vsebuje zdravilno učinkovino tigeciklin.
The CHMP's main concern was lack of compliance with Good Manufacturing Practice (GMP) by the manufacturing site for the medicine's active substance. 
Glavni pomislek odbora CHMP je bil, da lokacija proizvodnje zdravilne učinkovine zdravila ni dovolj skladna z dobro proizvodno prakso (GMP).
It was to be available as a powder to make a solution for infusion (drip) into a vein. 
Na voljo naj bi bilo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
This is because Tigecycline Accord is given by infusion into a vein, so the active substance is delivered straight into the bloodstream. 
Razlog za to je dejstvo, da se zdravilo Tigecycline Accord daje z infundiranjem v veno, zaradi česar zdravilna učinkovina vstopi neposredno v krvni obtok.
The active substance in Tigecycline Accord and Tygacil, tigecycline, is one of a group of antibiotics called ‘glycylcyclines'. 
Zdravilna učinkovina v zdravilih Tigecycline Accord in Tygacil, tigeciklin, spada v skupino antibiotikov, imenovanih „glicilciklini“.
How does Tigecycline Accord work? 
Kako zdravilo Tigecycline Accord deluje?
What is Tigecycline Accord? 
Kaj je zdravilo Tigecycline Accord?
Do not take more medicine than prescribed. 
Ne jemljite več zdravila kot je predpisano.
If you are an elderly patient (over 65 years of age), you should take Pregabalin Sandoz GmbH normally except if you have problems with your kidneys. 
Če ste starejši bolnik (nad 65 let), lahko jemljete zdravilo Pregabalin Sandoz GmbH normalno, razen če imate težave z ledvicami.
Pregabalin Sandoz GmbH should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). 
Zdravila Pregabalin Sandoz GmbH se ne sme uporabljati med nosečnostjo, razen če je nujno potrebno (če koristi za mater jasno prevladajo nad možnim tveganjem za plod).
• Changes in the recording of electrical changes (ECG) in the heart which correspond to heart rhythm disturbances. 
• Spremembe zapisa elektrokardiograma (EKG), ki kažejo na motnje srčnega ritma.
Do not take Pregabalin Sandoz GmbH: If you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Pregabalin Sandoz GmbH: Če ste alergični na pregabalin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics ATC code: N03AX16 
Farmakoterapevtska skupina: antiepileptiki, drugi antiepileptiki, oznaka ATC: N03AX16.
Other medicines and Pregabalin Sandoz GmbH Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Druga zdravila in zdravilo Pregabalin Sandoz GmbH Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
If you have the impression that the effect of Pregabalin Sandoz GmbH is too strong or too weak, talk to your doctor or pharmacist. 
Če imate občutek, da je učinek zdravila Pregabalin Sandoz GmbH premočan ali prešibak, se posvetujte z zdravnikom ali s farmacevtom.
• A small number of people being treated with anti-epileptics such as Pregabalin Sandoz GmbH have had thoughts of harming or killing themselves. 
• Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Pregabalin Sandoz GmbH, so se pojavile misli na samopoškodovanje ali samomor.
Pregabalin Sandoz GmbH is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment. 
Zdravilo Pregabalin Sandoz GmbH ni namenjeno temu, da bi ga jemali samo, temveč ga je vedno treba uporabljati v kombinaciji z drugimi zdravili proti epilepsiji.
• Pregabalin Sandoz GmbH may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. 
• Uporaba zdravila Pregabalin Sandoz GmbH lahko povzroči zamegljenost ali izgubo vida ali druge spremembe vida, med katerimi so mnoge začasne.
Each hard capsule contains either 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg or 300 mg pregabalin. 
Ena trdakapsula vsebuje 25mg, 50mg, 75mg, 100mg, 150mg, 200 mg, 225 mg ali 300 mg pregabalina.
If you take more Pregabalin Sandoz GmbH than you should Call your doctor or go to the nearest hospital emergency unit immediately. 
Če ste vzeli večji odmerek zdravila Pregabalin Sandoz GmbH, kot bi smeli Pokličite svojega zdravnika ali nemudoma pojdite v ambulanto za nujno pomoč najbližje bolnišnice.
The degree of dizziness, sleepiness and decreased concentration may be increased if Pregabalin Sandoz GmbH is taken together with medicines containing: 
Omotica, zaspanost ali zmanjšanje sposobnosti koncentracije se lahko stopnjujejo, če zdravilo Pregabalin Sandoz GmbH vzamemo skupaj z zdravili, ki vsebujejo:
Pregabalin Sandoz GmbH 25 mg hard capsules Pregabalin Sandoz GmbH 50 mg hard capsules Pregabalin Sandoz GmbH 75 mg hard capsules Pregabalin Sandoz GmbH 100 mg hard capsules Pregabalin Sandoz GmbH 150 mg hard capsules Pregabalin Sandoz GmbH 200 mg hard capsules Pregabalin Sandoz GmbH 225 mg hard capsules Pregabalin Sandoz GmbH 300 mg hard capsules Pregabalin 
Pregabalin Sandoz GmbH 25 mg trde kapsule Pregabalin Sandoz GmbH 50 mg trde kapsule Pregabalin Sandoz GmbH 75 mg trde kapsule Pregabalin Sandoz GmbH 100 mg trde kapsule Pregabalin Sandoz GmbH 150 mg trde kapsule Pregabalin Sandoz GmbH 200 mg trde kapsule Pregabalin Sandoz GmbH 225 mg trde kapsule Pregabalin Sandoz GmbH 300 mg trde kapsule pregabalin
Pregabalin Sandoz GmbH with food, drink and alcohol Pregabalin Sandoz GmbH capsules may be taken with or without food. 
Zdravilo Pregabalin Sandoz GmbH skupaj s hrano, pijačo in alkoholom Kapsule Pregabalin Sandoz GmbH lahko jemljete s hrano ali brez nje.
These symptoms may occur more commonly or severely if you have been taking Pregabalin Sandoz GmbH for a longer period of time. 
Ti znaki se lahko pojavljajo bolj pogosto in z večjo izrazitostjo, če ste zdravilo Pregabalin Sandoz GmbH jemali daljši čas.
Pregabalin Sandoz GmbH and certain other medicines may influence each other (interaction). 
Zdravilo Pregabalin Sandoz GmbH in določena druga zdravila imajo lahko medsebojno delovanje (interakcije).
The safety and efficacy of pregabalin in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. 
Varnost in učinkovitost pregabalina pri otrocih, starih do 12 let, in pri mladostnikih (12-17 let) nista bili dokazani.
If while taking Pregabalin Sandoz GmbH you notice decreased urination, you should tell your doctor as stopping the medicine may improve this. 
Če med jemanjem zdravila Pregabalin Sandoz GmbH zasledite zmanjšano izločanje urina, morate to povedati svojemu zdravniku, saj se lahko s prenehanjem jemanja zdravila stanje izboljša.
Pregabalin Sandoz GmbH is available in the following presentations: PVC/PVDC//Alu blisters packed in carton. 
Zdravilo Pregabalin Sandoz GmbH je na voljo v naslednjih pakiranjih: PVC/PVDC/aluminijski pretisni omot v škatli.
• When Pregabalin Sandoz GmbH is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g. constipation, blocked or paralysed bowel). 
• Ob sočasni uporabi zdravila Pregabalin Sandoz GmbH z ostalimi zdravili, ki lahko povzročijo zaprtost (kot so nekatera zdravila proti bolečinam), obstaja možnost pojava prebavnih težav (npr. zaprtje, zaprto ali paralizirano črevo).
• There have been reports of heart failure in some patients when taking pregabalin ; these patients were mostly elderly with cardiovascular conditions. 
• Pri nekaterih bolnikih, ki so jemali pregabalin, so opisani primeri srčnega popuščanja; večinoma je šlo za starejše bolnike s srčnožilnimi boleznimi.
For three times a day take Pregabalin Sandoz GmbH once in the morning, once in the afternoon and once in the evening, at about the same time each day. 
Če jemljete zdravilo Pregabalin Sandoz GmbH trikrat na dan, ga vzemite enkrat zjutraj, enkrat popoldne in enkrat zvečer, in sicer vsak dan ob približno istem času.
Your doctor will prescribe Pregabalin Sandoz GmbH for you to help treat your epilepsy when your current treatment is not controlling your condition. 
Zdravnik bo predpisal zdravilo Pregabalin Sandoz GmbH kot pomoč za zdravljenje epilepsije, če zdravila, ki jih trenutno uporabljate, bolezni ne obvladujejo.
Epilepsy: Pregabalin Sandoz GmbH is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults. 
Epilepsija: Zdravilo Pregabalin Sandoz GmbH se uporablja za zdravljenje določene oblike epilepsije (parcialnih napadov s sekundarno generalizacijo ali brez nje) pri odraslih.
There have been postmarketing reports of congestive heart failure in some patients receiving pregabalin. 
Kongestivno srčno popuščanje V obdobju trženja so poročali o primerih kongestivnega srčnega popuščanja pri nekaterih bolnikih, ki so dobivali pregabalin.
The incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased in the treatment of central neuropathic pain due to spinal cord injury (see section 4.4). 
Incidenca neželenih učinkov na splošno, neželenih učinkov, povezanih z osrednjim živčnim sistemom, in še posebno somnolence je bila povečana pri zdravljenju centralne nevropatske bolečine kot posledice poškodbe hrbtenjače (glejte poglavje 4.4).
Pregabalin Sandoz GmbH may be taken with or without food. 
Zdravilo Pregabalin Sandoz GmbH se lahko jemlje s hrano ali brez nje.
Pregabalin Sandoz GmbH should not be taken during pregnancy or when breast-feeding, unless you are told otherwise by your doctor. 
Zdravila Pregabalin Sandoz GmbH ne smete uporabljati med nosečnostjo ali dojenjem, razen če vam tako svetuje zdravnik.
Take your box or bottle of Pregabalin Sandoz GmbH capsules with you. 
S seboj vzemite svojo škatlo ali plastenko kapsul zdravila Pregabalin Sandoz GmbH.
It is important to take your Pregabalin Sandoz GmbH capsules regularly at the same time each day. 
Če ste pozabili vzeti zdravilo Pregabalin Sandoz GmbH Pomembno je, da kapsule Pregabalin Sandoz GmbH jemljete redno, vsak dan ob istem času.